Cleo Diagnostics (ASX:COV) is attempting to bring to market a simple blood test for the accurate and early diagnosis of ovarian cancer based on the novel patented CXCL10 biomarker, which is produced early and at high levels by ovarian cancers but is largely absent in nonmalignant disease. The test aims to distinguish benign from malignant growths in a standard format that will be readily compatible with existing equipment used by diagnostic laboratories worldwide | Investor presentation: https://cdn-api.markitdigital.com/apiman-gateway/ASX/asx-research/1.0/file/2924-02774453-3A636747
GGE
0.004
100%
DTM
0.003
-40%
FHS
0.005
66.7%
SRH
0.175
-35.2%
TMK
0.003
50%
CRB
0.004
-33.3%
FIN
0.007
40%
JAV
0.002
-33.3%
KPO
0.007
40%
FNR
0.12
-29.4%
CMD
0.022
37.5%
WBE
0.005
-28.6%
DDT
0.004
33.3%
MDR
0.096
-26.2%
TASDA
0.02
33.3%
BNL
0.006
-25%
PCL
0.013
30%
HLS
1.155
-25%
ENV
0.009
28.6%
PHO
0.054
-22.9%
VRX
0.057
26.7%
KRR
0.007
-22.2%
CAV
0.005
25%
AMS
0.004
-20%
RLG
0.005
25%
IPB
0.004
-20%
TEM
0.005
25%
RGL
0.004
-20%
TNC
0.185
23.3%
JLL
0.38
-18.3%
FRS
0.047
20.5%
CHM
0.005
-16.7%
CRI
0.018
20%
IFG
0.005
-16.7%
CUF
0.006
20%
ODE
0.005
-16.7%
TG1
0.024
20%
AVH
2.5
-16.4%
THB
0.012
20%
MDI
0.018
-14.3%
